TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside.
Demodex Blepharitis: Blepharitis is a common ocular condition that is characterized by inflammation of the eyelid margin, redness and ocular irritation. Demodex blepharitis is caused by infestation of Demodex mites, the most common ectoparasite found on humans. There are no approved therapeutics for the treatment of Demodex blepharitis.
Meibomian Gland Disease (MGD): The Meibomian glands in the eyelids secrete lipids that form the superficial layer of tear film in the eyes. MGD is characterized, in part, by a widespread clogging of these glands, which may alter the tear film and lead to eye irritation, inflammation and ocular surface disease. There are no approved therapeutics for MGD, which is one of the leading causes of dry eye disease. Clinical signs of MGD have been shown to be correlated with infestation of one species of Demodex mite, Demodex brevis. TP-03 is being investigated as a potential treatment to relieve some of the key elements of MGD by eliminating the Demodex brevis mites.
Demodex blepharitis and Meibomian Gland Disease are common eye conditions. Currently, there an estimated 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China.
LianBio is pursuing a registration strategy for TP-03 in China initially for the treatment of Demodex blepharitis. LianBio also plans to join the future global development program for TP-03 for the treatment of Meibomian Gland Disease.